Drug Development

With cash dwindling and a pivotal trial result looming after a recent failure, Vistagen brings a seasoned drug developer aboard to navigate the turbulence.

With Phase 3 results for Levosimendan imminent and its cash runway secured, Tenax Therapeutics faces a make-or-break moment in the PH-HFpEF space.

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

Karyopharm's stock plummets after a key cancer trial fails, forcing a strategic retreat and a hard pivot toward more promising assets in its pipeline.

With $217M in the bank, SAB Biotherapeutics has silenced liquidity fears. Now, all eyes are on its novel T1D drug and the unproven promise of its cow-powered tech.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

New patents in Europe and Australia grant Savara long-term protection for a vital new therapy, offering hope to patients with a rare, debilitating lung disease.

MIRA Pharmaceuticals moves two novel drug candidates closer to human trials, a key de-risking event for investors eyeing the massive pain and obesity markets.

Maia Fertility lands key VC funding to prove its Ferizyme™ platform in cattle, paving a strategic, data-driven path toward human reproductive medicine.

Clinical research leader Novotech offers a strategic roadmap for biotech and pharma, aiming to de-risk and accelerate the complex world of autoimmune drug development.

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

Basking Biosciences' BB-031 targets a key clotting protein, dissolving clots hours later than current drugs. With a unique reversal agent, it could transform stroke care.

AB2 Bio's partnership with Nippon Shinyaku for Tadekinig alfa signals a new era for ultra-rare pediatric care and highlights a savvy biotech financing strategy.

With FDA clearance for IKS04, Iksuda Therapeutics unveils a novel co-dosing strategy to deliver a potent payload past notorious tumor barriers.

Lōkahi Therapeutics aims to turn 15 injections into one for its pain drug LT-100, a move that could transform patient care and unlock major commercial value.

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

Clene Inc. heads to the Canaccord Growth Conference with promising ALS data and a clear regulatory path, but faces a critical test of investor confidence.

As Akebia Therapeutics preps its Q2 report, all eyes are on Vafseo's uptake, a declining Auryxia, and a costly R&D push into rare kidney diseases.

With a novel drug targeting an unaddressed cause of glaucoma, Qlaris Bio adds a seasoned expert to its board, signaling a pivotal push toward market entry.

Processa Pharmaceuticals acquires Vidya Therapeutics and its key asset, VT-7208, backed by a $200M financing that radically overhauls the company's strategy.